Symbiotec eyes IPO to give exit to PE investors; can it command a high valuation?

By Debjyoti Roy

  • 17 Oct 2024
Premium

Bulk drug maker Symbiotec Pharmalab is planning to explore the possibility of floating an initial public offering in the next financial year, it is gathered. The Indore-based firm is eyeing to kickstart its public listing plans next year which will likely provide an exit to its private equity backers MOAlts and ......

This is a Premium article. Please subscribe or log in to read the full story!

Here's a selection of our recent premium content.

Already a member? Click here to log in.